MX2022008428A - Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo. - Google Patents

Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo.

Info

Publication number
MX2022008428A
MX2022008428A MX2022008428A MX2022008428A MX2022008428A MX 2022008428 A MX2022008428 A MX 2022008428A MX 2022008428 A MX2022008428 A MX 2022008428A MX 2022008428 A MX2022008428 A MX 2022008428A MX 2022008428 A MX2022008428 A MX 2022008428A
Authority
MX
Mexico
Prior art keywords
dimethylpent
pyrazolo
piperidine
fluoro
carbonyl
Prior art date
Application number
MX2022008428A
Other languages
English (en)
Inventor
Pasit Phiasivongsa
Dolca Thomas
Katherine Chu
Claire Langrish
Jyoti Wadhwa
Jason Carbol
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022008428A publication Critical patent/MX2022008428A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente memoria se proporcionan composiciones farmacéuticas tópicas, por ejemplo, para su aplicación en la piel de un sujeto, que comprenden (R)-2-(3-(4-amino-3-(2-fluoro-4-fenox ifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidina-1-carbonil)-4 ,4-dimetilpent-2-enonitrilo (Compuesto (I)), métodos de preparación de las mismas y métodos de uso de las mismas, por ejemplo, para el tratamiento de diversos trastornos dermatológicos.
MX2022008428A 2020-01-08 2021-01-07 Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo. MX2022008428A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958616P 2020-01-08 2020-01-08
US202063003536P 2020-04-01 2020-04-01
PCT/US2021/012507 WO2021142124A1 (en) 2020-01-08 2021-01-07 Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022008428A true MX2022008428A (es) 2022-08-08

Family

ID=74626093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008428A MX2022008428A (es) 2020-01-08 2021-01-07 Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo.

Country Status (13)

Country Link
US (2) US11583533B2 (es)
EP (1) EP4087537A1 (es)
JP (1) JP2023510244A (es)
KR (1) KR20220124753A (es)
CN (1) CN115605181A (es)
AU (1) AU2021205248A1 (es)
BR (1) BR112022012974A2 (es)
CA (1) CA3163850A1 (es)
CO (1) CO2022009437A2 (es)
IL (1) IL294537A (es)
MX (1) MX2022008428A (es)
TW (1) TW202142237A (es)
WO (1) WO2021142124A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342048A (zh) * 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2836449C (en) 2011-05-17 2021-04-27 The Regents Of The University Of California Kinase inhibitors
SI2710005T1 (sl) 2011-05-17 2017-03-31 Principia Biopharma Inc. Zaviralci tirozinske kinaze
CA2874461C (en) 2012-06-18 2021-10-12 Principia Biopharma Inc. Formulations containing reversible covalent compounds
WO2014022569A1 (en) * 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
SI3181567T1 (sl) 2012-09-10 2019-09-30 Principia Biopharma Inc. Spojine pirazolopirimidina, kot inhibitorji kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
MA41197B1 (fr) * 2014-12-18 2021-01-29 Principia Biopharma Inc Traitement de le pemphigus
US20170224688A1 (en) 2016-02-04 2017-08-10 Acerta Pharma B.V. Methods of Using BTK Inhibitors to Treat Dermatoses
EP3478273A1 (en) 2016-06-29 2019-05-08 Principia Biopharma Inc. Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
KR20220124753A (ko) 2022-09-14
EP4087537A1 (en) 2022-11-16
CN115605181A (zh) 2023-01-13
US11583533B2 (en) 2023-02-21
TW202142237A (zh) 2021-11-16
BR112022012974A2 (pt) 2022-09-13
US20230277542A1 (en) 2023-09-07
CA3163850A1 (en) 2021-07-15
CO2022009437A2 (es) 2022-12-09
WO2021142124A1 (en) 2021-07-15
US20210205313A1 (en) 2021-07-08
IL294537A (en) 2022-09-01
JP2023510244A (ja) 2023-03-13
AU2021205248A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
TW200635588A (en) 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
WO2006044860A3 (en) Thiadiazole compounds and methods of use
SI1532974T1 (sl) Zmes, ki vsebuje 6-(3-(1-adamantil)-4-metoksifenil)-2-naftensko kislino, za zdravljenje dermatoloških motenj
HK1149764A1 (es)
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
WO2006068768A3 (en) Methods and compositions for treating conditions
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2006081431A3 (en) Compounds for treating inflammatory and demyelinating diseases
WO2005115432A3 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
GB0606805D0 (en) Organic compounds
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2007028104A3 (en) Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
MX2022008428A (es) Composiciones farmaceuticas topicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirim idin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo.
WO2005000233A3 (en) Novel therapeautic agents for the treatment of cancer, metabolic diseases and skin disorders
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
JP2020189828A (ja) 外用剤組成物
WO2023114369A3 (en) Topical formulations of pi3k-delta inhibitors